Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at email@example.com. Follow @suzannewriter on Twitter.
- Contact Suzanne
- Follow Suzanne on Google+
Articles by Suzanne Elvidge
Scancell, a U.K. spinout from the University of Nottingham, has completed recruitment for the Phase I trial of SCIB1, its therapeutic DNA vaccine for the treatment of melanoma.
Taiwanese researchers are developing a virus-based RSV vaccine that could complete preclinical studies next year, and has already shown signs of efficacy.
There are no dengue virus vaccines so far, but new research from the University of North Carolina and Vanderbilt University could help speed vaccines to the market.
According to the U.K.'s The Telegraph, Bavarian Nordic's Prostvac prostate cancer vaccine has started a Phase III clinical trial in the U.K.
Biovest has chosen Canada for the first submission for approval of its personalized cancer vaccine, BiovaxID. The vaccine could become the first cancer vaccine marketed for lymphoma patients.
The Thai trial, also known as RV144, was published in the NEJM in 2009 and is the subject of a new study, which has tried to unpack just how that protective effect worked.
Creating vaccines that bind to a damaged cell-recognition molecule called Clec9A could trick dendritic cells into thinking they have encountered a damaged cell and help to launch an immune response.
Researchers are developing a DNA-based vaccine targeting Derf1 from the dust mite Dermatophagoides farina.
The deal cuts the price for the vaccines 67 percent and means vaccines for 70 million children in the world's 40 poorest countries by 2016.
The Israeli company Vaxil BioTherapeutics is making the most of the fact that most cancers have the MUC1 antigen on the surface of the cells with its experimental peptide vaccine ImMucin.